title: Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.
abstract: OBJECTIVE
  We present our data comparing retrospectively the efficacy of abiraterone and cabazitaxel in patients who progress after docetaxel treatment.
  
  
  METHODS
  The study included 56 patients diagnosed with hormone-refractory metastatic prostate cancer who were previously treated with abiraterone therapy at four oncology centers in Turkey.
  
  
  RESULTS
  With abiraterone, the patients had a median progression-free survival (PFS) of 5.9 months (95% confidence interval (CI) for hazard ratio (HR) (4.4-7.4)) and an overall survival of 13.4 months (95% CI for HR (5.5-21.3)). When we compared the disease-free survival (DFS) of reference patients treated with cabazitaxel as a second-line treatment with those receiving second-line abiraterone therapy, there was no significant difference. (PFS = 5.9 months with cabazitaxel vs. 6.7 months with abiraterone, P = 0.213).
  
  
  CONCLUSIONS
  This study has shown that in our experience abiraterone acetate is an effective agent in metastatic castration-resistant prostate cancer (mCRPC) regardless of the line of treatment.
authors.affiliation: Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Gunduz
authors.forename: H
authors.initials: H
authors.lastname: Bozcuk
authors.forename: M
authors.initials: M
authors.lastname: Yıldız
authors.forename: S S
authors.initials: SS
authors.lastname: Goksu
authors.forename: M
authors.initials: M
authors.lastname: Uysal
authors.forename: D
authors.initials: D
authors.lastname: Arslan
authors.forename: A M
authors.initials: AM
authors.lastname: Tatlı
authors.forename: H
authors.initials: H
authors.lastname: Mutlu
authors.forename: H S
authors.initials: HS
authors.lastname: Coşkun
authors.forename: M
authors.initials: M
authors.lastname: Ozdogan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000736:Androstenes / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000736:Androstenes; C089740:abiraterone